

Editorial

- 120** Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation

Ameenathul M. Fawzy, MB, Brian Olshansky, MD, Gregory Y. H. Lip, MD, Liverpool, United Kingdom and Iowa City, Iowa

Trial Designs

- 11** The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design

Kristina Lambrakis, John K. French, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, and Derek P. Chew, Adelaide, Sydney, Brisbane, Perth, Melbourne, Australia; Toronto, Canada; and Auckland, New Zealand

- 37** BETAblocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study

John Munkhaugen, MD, PhD, Vidar Ruddox, MD, PhD, Sigrun Halvorsen, MD, PhD, Toril Dammen, MD, PhD, Morten W. Fagerland, PhD, Kjersti H. Hernæs, Cand. Econ, Nils Tore Veithe, PhD, Eva Prescott, MD, DMSc, Svend Eggert Jensen, MD, PhD, Olaf Rødevand, MD, PhD, Jarle Jortveit, MD, PhD, Bjørn Bendz, MD, PhD, Henrik Schirmer, MD, PhD, Lars Køber, MD, PhD, Hans Erik Bøtker, MD, PhD, Alf Inge Larsen, MD, PhD, Kjell Vikenes, MD, PhD, Terje Steigen, MD, PhD, Rune Wiseth, MD, PhD, Terje Pedersen, MD, PhD, Thor Edvardsen, MD, PhD, Jan Erik Otterstad, MD, PhD, and Dan Atar, MD, PhD, Drammen, Oslo, Vestfold Hospital Trust, LHL Hospital Gardermoen, Arendal, Lørenskog, Stavanger, Bergen, Tromsø, Trondheim, Norway; Copenhagen, Aalborg; and Aarhus University Hospital Skejby, Denmark

- 55** Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: Design and baseline results of the SUPPORT-HF 2 randomized trial

SUPPORT-HF 2 Investigators and Committees

Clinical Investigations

- 1** Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction

Hoang V. Tran, MD, MPH, Arlene S. Ash, PhD, Joel M. Gore, MD, Chad E. Darling, MD, MS, Catarina I. Kiefe, PhD, MD, and Robert J. Goldberg, PhD, Worcester, MA

- 21** Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials

Christoffer Polcwiartek, MD, Pia Behrndtz, RN, Diploma of Health, Ann Hass Andersen, RN, Marianne Bregendahl, RN, Helle Pedersen Hald, RN, and Svend Eggert Jensen, MD, PhD, Aalborg, Denmark

- 28** Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial

Neha J. Pagidipati, MD, MPH, Adrian Coles, PhD, Kshipra Hemal, BS, Kerry L. Lee, PhD, Rowena J. Dolor, MD, MHS, Patricia A. Pellikka, MD, Daniel B. Mark, MD, Manesh R. Patel, MD, Sheldon E. Litwin, MD, Melissa A. Daubert, MD, Svati H. Shah, MD, Udo Hoffmann, MD, and Pamela S. Douglas, MD, on behalf of the PROMISE Investigators Durham, NC; Rochester, MN; Charleston, SC; and Boston, MA

Contents *continued*

- 47** Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals
Trajen Head, PhD, Lisa Henn, PhD, Victor P. Andreev, PhD, DSc, Edward E. Herderick, Sapna K. Deo, PhD, Sylvia Daunert, PhD, and Pascal J. Goldschmidt-Clermont, MD, FL, MI, and OH, USA
- 65** Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial
Claes Held, MD, PhD, Harvey D. White, DSc, Ralph A.H. Stewart, MD, PhD, Richard Davies, MS, Shani Sampson, BA, Karen Chiswell, PhD, Adam Silverstein, MS, Renato D. Lopes, MD, PhD, Ulrika Heldestad, BSN, Andrzej Budaj, MD, PhD, Kenneth W. Mahaffey, MD, PhD, and Lars Wallentin, MD, PhD, on behalf of the STABILITY Investigators Uppsala, Sweden; Auckland, New Zealand; King of Prussia, PA; Durham, NC; Warsaw, Poland and Stan
- 74** The association of pre- and posthospital medication adherence in myocardial infarction patients
Jacob A. Doll, MD, Anne S. Hellkamp, MS, Laine Thomas, PhD, Gregg C. Fonarow, MD, Eric Peterson, MD MPH, and Tracy Y. Wang, MD MHS Msc, Seattle, WA; Durham, NC; and Los Angeles, CA
- 81** The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
C. Michael Gibson, MS, MD, Mathieu Kerneis, MD, Megan K. Yee, MPH, Yazan Daaboul, MD, Serge Korjian, MD, Ali Poyan Mehr, MD, Pierluigi Tricoci, MD, John H. Alexander, MD, MHS, John J. P. Kastelein, MD, PhD, Roxana Mehran, MD, Christoph Bode, MD, Basil S. Lewis, MD, Ravindra Mehta, MD, Danielle Duffy, MD, John Feaster, MS, Majdi Halabi, MD, Dominick J. Angiolillo, MD, PhD, Daniel Duerschmied, MD, Ton Oude Ophuis, MD, and Bela Merkely, MD, Boston, MA; Durham, NC; Amsterdam, Nijmegen, the Netherlands; New York, NY; Freiburg, Germany; Haifa, Tsfat, Israel; San Diego, CA; King of Prussia, PA; Gainesville, FL and Budapest, Hungary
- 91** The prognostic value of various biomarkers in adults with pulmonary hypertension; a multibiomarker approach
Laurie W. Geenen, BSc, Vivian J. M. Baggen, MD, PhD, Thomas Koudstaal, MD, Karin A. Boomars, MD, PhD, Jannet A. Eindhoven, MD, PhD, Eric Boersma, MSc, PhD, FESC, Jolien W. Roos-Hesselink, MD, PhD, and Annemien E. van den Bosch, MD, PhD, Rotterdam, the Netherlands
- 100** Modes of death and prognostic outliers in chronic heart failure
Marco Canepa, MD, PhD, Pietro Ameri, MD, PhD, Donata Lucci, MSc, Gian Luigi Nicolosi, MD, Roberto Marchioli, MD, Maurizio Porcu, MD, Gianni Tognoni, MD, Maria Grazia Franzosi, BiOId, Roberto Latini, MD, Attilio Maseri, MD, Luigi Tavazzi, MD, and Aldo Pietro Maggioni, MD, on behalf of the GISSHF Investigators Genova, Florence, Pordenone, Milan, Cagliari, Florence and Cotignola, Italy
- 110** Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort
Alexander C. Perino, MD, George C. Leef, MD, Andrew Cluckey, MD, Fahd N. Yunus, MD, Mariam Askari, BS, Paul A. Heidenreich, MD, MS, Sanjiv M. Narayan, MD, PhD, Paul J. Wang, MD, and Mintu P. Turakhia, MD, MAS, Stanford, and Palo Alto, CA
- 123** Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multimorbidity: Insights from the ARISTOTLE trial
Karen P. Alexander, MD, Marc A. Brouwer, MD, PhD, Hillary Mulder, MS, Dragos Vinereanu, MD, PhD, Renato D. Lopes, MD, PhD, MHS, Marco Proietti, MD, Sana M. Alkhatib, MD, MHS, Ziad Hijazi, MD, PhD, Sigrun Halvorsen, MD, PhD, Elaine M. Hylek, MD, MPH, Freek W. A. Verheugt, MD, John H. Alexander, MD, MHS, Lars Wallentin, MD, PhD, and Christopher B. Granger, MD, on behalf of the ARISTOTLE Investigators Durham, NC; Nijmegen, The Netherlands; Bucharest, Romania; Rome, Italy; Uppsala, Sweden; Oslo, Norway; and Boston, MA